nafamostat has been researched along with Hemorrhagic Disorders in 2 studies
nafamostat: inhibitor of trypsin, plasmin, pancreatic kallikrein, plasma kallikrein & thrombin; strongly inhibits esterolytic activities of C1r & C1 esterase complement-mediated hemolysis; antineoplastic
Hemorrhagic Disorders: Spontaneous or near spontaneous bleeding caused by a defect in clotting mechanisms (BLOOD COAGULATION DISORDERS) or another abnormality causing a structural flaw in the blood vessels (HEMOSTATIC DISORDERS).
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 2 (100.00) | 18.2507 |
| 2000's | 0 (0.00) | 29.6817 |
| 2010's | 0 (0.00) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| Kinugasa, E | 1 |
| Akizawa, T | 1 |
| Nakashima, Y | 1 |
| Wakasa, M | 1 |
| Koshikawa, S | 1 |
| Takahashi, H | 1 |
| Shibata, A | 1 |
2 other studies available for nafamostat and Hemorrhagic Disorders
| Article | Year |
|---|---|
Nafamostat as anti-coagulant for membrane plasmapheresis in high bleeding risk patients.
Topics: Adolescent; Adult; Aged; Anticoagulants; Benzamidines; Blood Cell Count; Blood Coagulation; Extracor | 1992 |
[Bleeding tendency in chronic kidney failure with hemodialysis].
Topics: Benzamidines; Deamino Arginine Vasopressin; Estrogens; Factor VIII; Fibrinogen; Guanidines; Hemorrha | 1992 |